Analysis of large-cell lung cancer and its metastasis
Integrative Analysis of Large-cell Lung Carcinoma
Shanghai 10th People's Hospital · NCT02917369
This study is trying to understand large-cell lung cancer and how it spreads by comparing normal lung tissue to cancer samples, including those that have spread to the liver.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Shanghai 10th People's Hospital (other) |
| Drugs / interventions | chemotherapy |
| Locations | 3 sites (Ganzhou, Jiangxi and 2 other locations) |
| Trial ID | NCT02917369 on ClinicalTrials.gov |
What this trial studies
This study conducts an integrative analysis of large-cell lung cancer (LCLC) by examining the proteomes of paired normal lung tissues and LCLC samples, both with and without liver metastasis. The methodology includes sequencing transcriptomes, whole exome sequencing, and single nucleotide polymorphism (SNP) array profiling for triplets of normal lung tissue, primary LCLC carcinoma, and its matched metastasis. Additionally, the study will analyze genomic data from lung cancer previously characterized by The Cancer Genome Atlas (TCGA) to perform integrated proteogenomic analyses.
Who should consider this trial
Good fit: Ideal candidates for this study are patients aged 75 years or younger with histologically confirmed large-cell lung cancer and a WHO performance status of 0 or 1.
Not a fit: Patients over the age of 75, those with severe major organ dysfunction, or those who have received prior cancer chemotherapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of LCLC and its metastasis, potentially leading to improved treatment strategies.
How similar studies have performed: Other studies utilizing integrative analyses of cancer genomics have shown promise, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≤ 75 years with histologically proven LCLC * No severe major organ dysfunction * World Health Organization (WHO) performance status of 0 or 1 * No prior cancer chemotherapy Exclusion Criteria: * Age ≥ 76 * Severe major organ dysfunction * WHO performance status of \>1 * Prior cancer chemotherapy
Where this trial is running
Ganzhou, Jiangxi and 2 other locations
- Ganzhou City People's Hospital — Ganzhou, Jiangxi, China (RECRUITING)
- Shanghai Tenth People's Hospital — Shanghai, Shanghai Municipality, China (RECRUITING)
- Shanghai Pulmonary Hospital — Shanghai, Shanghai Municipality, China (RECRUITING)
Study contacts
- Principal investigator: Da Fu, PhD — Shanghai 10th People's Hospital
- Study coordinator: Da Fu, PhD
- Email: fu800da900@126.com
- Phone: 00-86-21-66301604
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Lung Cancer, LCLC, Integrative Analysis, Metastasis